Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAnthem Medicaid PDL Coverage & Prior Auth | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAnthemPolicy N/A

    Medicaid-Approved Preferred Drug List (partial formulary entries)

    Customize your policy alerts

    Sign up for all Anthem policy alerts

    Know when Anthem releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists formulary entries and coverage notes (OTC, PA, QL, DO, AL, SP) for Anthem Medicaid in North Carolina; affects prescribers, pharmacies, and prior authorization staff responsible for dispensing and reimbursement.

    Policy Summary
    PayerAnthem
    PolicyMedicaid-Approved Preferred Drug List (partial formulary entries)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before prescribing or dispensing any product annotated 'PA' in the formulary.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+medication entries in this partial section
    multiplecoverage notes types
    NCapplicable state
    severalitems flagged PA

    Coverage summary & scope

    This formulary excerpt is a legend-style listing of dermatologic and topical products with administrative coverage annotations. Items are presented with shorthand Notes such as QL (quantity limit), OTC (over-the-counter), and PA/SP for biologic injectables; no explicit clinical exclusion language or medical necessity criteria are provided in this segment. Examples include topical antifungals and corticosteroids (e.g., clotrimazole, clobetasol propionate) and specialty biologic entries (e.g., DUPIXENT — Notes = PA; SP), where the Notes indicate administrative controls rather than in-text coverage rules.

    This portion of the legend lists miscellaneous oral products and macrolide antibiotics with Notes indicating administrative designations (for example, many tablet and suspension entries are shown without embedded clinical criteria). The extract shows OTC status applied to stool softeners and other items and does not include explicit exclusions or medical necessity statements for the listed medications.

    The device and consumables segment enumerates lancets, lancing devices, control solutions, and CGM sensors/readers with Notes such as OTC, QL, and where applicable PA. This is a legend listing only — it does not provide medical necessity criteria or step-therapy sequences; it signals that quantity limits and prior authorization processes may apply to certain device items but defers to the payer's authorization processes for specific clinical rules.

    This excerpt continues device and supply listings (meters, kits, alcohol swabs) annotated with administrative Notes (for example, meter kits annotated PA; OTC or lancets annotated OTC; QL). No explicit clinical exclusions are stated here — entries indicate which items are subject to quantity limits or prior authorization but do not contain the underlying coverage criteria.

    The ophthalmic and selected injectable/specialty segment lists eye care products and multiple sclerosis/neurologic injectables with administrative flags. Ophthalmic agents include lubricants and antihistamines marked OTC or QL, and LASTACAFT is shown with PA; OTC; QL. Injectable specialty therapies (e.g., AVONEX, BETASERON) are annotated PA; SP; QL. These Notes reflect utilization management and specialty routing; explicit clinical coverage or exclusion rules are not provided in this extract.

    Formulary codes, NDCs and coding notes

    Formulary product codes and notesmixed
    REPATHAREPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE - Notes = PA; QL
    VANCINvancomycin hcl oral capsule - Notes = QL
    ZYVOXlinezolid oral suspension/reconstituted and tablets - Notes = PA; QL
    ELLENCEELLENCE INTRAVENOUS SOLUTION - Notes = PA; SP
    MVASIMVASI INTRAVENOUS SOLUTION - Notes = PA; SP
    Specialty biologics (examples)mixed
    DUPIXENTDUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR — Notes = PA; SP
    DUPIXENTDUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE — Notes = PA; SP
    Dermatologic agents with prior authmixed
    PIMECROLIMUSpimecrolimus external cream — Notes = PA; AL; QL
    PODOFILOXpodofilox external solution — Notes = PA; QL
    Endocrine/rare disease specialty injectablesmixed
    NORDITROPINNORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN- INJECTOR — Notes = PA; SP; QL
    SELARSDISELARSDI SUBCUTANEOUS SOLUTION (and IV) — Notes = PA; SP; QL
    NDC/Coding not listed in these chunksmixed
    No codes listed
    inv-12: Quantity limits — multiple entries marked QL (unspecified limits here)
    ScopeMultiple formulary line-items are annotated 'QL' indicating quantity limits are applied (specific numeric limits not shown in this excerpt).

    Prior authorization, documentation and provider requirements

    Prior Authorization

    Prior authorization required

    Products annotated with 'PA' require prior authorization before claim payment. Claims for items marked PA may be denied if a prior authorization is not obtained and documented.

    • Trigger: any product line with Notes = PA
    • Examples: REPATHA, DUPIXENT, SELARSDI, AVONEX, DEXCOM sensors, OMNIPOD kits, AIMOVIG, EMGALITY, various oncology and specialty injectables
    Prior Authorization

    Prior authorization and specialty routing indicated

    PA and SP together indicate the product requires prior authorization and specialty routing (distribution through specialty pharmacy or site-of-care controls). For SP items, expect specialty handling and documentation requirements during the authorization process.

    • Trigger: Notes include both PA and SP
    • Examples: MVASI, DUPIXENT, ARANESP, ENSPRYNG, AVONEX, REBIF

    Legend & abbreviations

    inv-59: Over-the-counter (OTC) — definition and context
    DefinitionOTC = Over-the-counter; indicates product is available without a prescription and is shown with this coverage note in the formulary.
    Typical itemsCommon OTC entries include antihistamines, laxatives, vitamins/prenatals, and many topical lubricants and eye drops.
    Implication for coverageOTC designation in the legend signals non-prescription status; the payer may still apply QL or other limits as noted.
    inv-60: Prior Authorization (PA) — requires pre-approval
    DefinitionPA = Prior Authorization; coverage requires payer pre-approval when the 'PA' note appears next to a product.
    Common PA itemsExamples include REPATHA, certain injectable biologics, migraine injectables (Aimovig/Emgality), and selected device kits.

    Step therapy signals and presence

    Coverage noteImplication
    SP or PA noted on oncology/specialty agents (e.g., MVASI, mitoxantrone, vinorelbine)
    May imply specialty distribution or prior authorization controls; explicit step-therapy sequences are not provided in this listing
    Coverage noteImplication
    DO and AL annotations present on multiple oral and long-acting formulations (examples: clozapine entries, haloperidol, lithium products)
    DO (dispense/dispensing designation) and AL (age or additional limitation) suggest dispensing/program restrictions or age-based limits; no explicit step sequence is specified
    Coverage noteExamplesImplication
    PA; SP; QL
    ambrisentan; sildenafil; tadalafil (PA; SP; QL noted)
    Products marked PA (and often SP) require prior authorization and may be routed via specialty channels; step edits are not detailed in this excerpt
    Coverage noteImplication
    PA; AL; QL noted for some topical and dermatologic agents (e.g., pimecrolimus, podofilox)
    Annotation suggests prior authorization or requirement to try alternative/step therapies prior to coverage, though specific step requirements are not provided here
    Coverage noteImplication
    Multiple entries show PA, QL, or SP flags but no ordered step sequences (examples: various gout and hematologic agents)
    PA/QL/SP flags indicate utilization management (authorization, quantity limits, specialty routing) without explicit step-therapy sequences in this fragment
    Coverage noteExamplesImplication
    PA; QL
    Omnipod kits/pods (OMNIPOD 5 kits/pods) — Notes = PA; QL
    Device listings labeled PA and QL indicate prior authorization and quantity limits will apply before coverage; step sequencing is not specified
    Coverage noteExamplesImplication
    PA; QL
    AIMOVIG, EMGALITY and other migraine products annotated PA; QL
    Prior authorization and quantity limits may be required for coverage of some migraine acute and preventive therapies; explicit step rules are not included here

    Quantity limit flags and affected items

    inv-105: many OTC antihistamines and common medications — QL indicated in fragment
    Many OTC antihistaminesMultiple OTC antihistamines (cetirizine, loratadine, diphenhydramine formulations) are present and flagged with QL in the legend.
    ExamplesCetirizine products (child and adult liquid/tablet/chewable) and loratadine child solutions are shown OTC; QL.
    Coverage implicationEven common OTC antihistamines may be subject to quantity limits per the formulary notes.
    inv-106: REPATHA — QL indicated
    REPATHA annotationREPATHA (evolocumab) entries (prefilled syringe and SureClick auto-injector) are annotated 'PA; QL' in the legend.
    ImplicationPrior authorization and quantity limits apply to REPATHA per the formulary notes; PA must be obtained for coverage.

    Specialty channel, infusion and site restrictions

    Note

    SP may imply infusion center/site‑of‑care management

    Specialty products may be managed through infusion centers or specialty distribution channels; the legend’s SP flag indicates specialty handling though site‑specific rules are not detailed here.

    Note

    SP items require specialty pharmacy management

    Products annotated SP are handled via specialty pharmacy channels and require the appropriate specialty routing and documentation.

    Billing Rule

    Route SP products through specialty pharmacy

    Policy background & scope

    Background: this fragment is a partial Preferred Drug List (PDL) legend that enumerates pharmaceuticals and devices for Anthem Medicaid (North Carolina) with shorthand Notes used to indicate coverage controls. The listing format emphasizes administrative flags — for example, PA (prior authorization), QL (quantity limit), OTC (over-the-counter), SP (specialty) — and does not include the full medical necessity criteria or step-therapy sequences for the named products. Providers and pharmacy staff should follow the payer's PA and QL processes where those Notes appear to ensure proper adjudication.

    Policy Summary
    PayerAnthem
    PolicyMedicaid-Approved Preferred Drug List (partial formulary entries)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before prescribing or dispensing any product annotated 'PA' in the formulary.
    SourceLink
    On This Page
    Coverage summary & scopeFormulary codes, NDCs and coding notesPrior authorization, documentation and provider requirementsLegend & abbreviationsStep therapy signals and presenceQuantity limit flags and affected itemsSpecialty channel, infusion and site restrictionsPolicy background & scope

    This section lists acid-reducer and gastrointestinal products (including OTC-designated proton pump inhibitor formulations) with Notes indicating OTC status for many strengths. The entries are listing-level with administrative annotations (OTC, QL) rather than formal clinical coverage criteria or exclusion statements.

    Examples (topicals & OTC) Clobetasol propionate (cream/gel/ointment/solution) and many OTC topical products are flagged QL.
    Common device/consumablesLancets, insulin syringes, alcohol prep pads and control solutions are repeatedly marked QL across device listings.
    Specialty injectablesSelected specialty injectables and biologics (e.g., some PA; SP entries) also include QL annotations.
    Formulary usageThe 'QL' note signals the payer enforces quantity limits during pharmacy adjudication and may require documentation for quantities above the limit.
    inv-13: Quantity Limit presence — various products annotated QL in these chunks
    Presence summaryNumerous products across categories are annotated 'QL' in the legend (e.g., REPATHA, topical agents, device consumables), indicating quantity limits are present though exact limits are not listed here.
    Cardiovascular & cardiac glycosidesAgents such as nifedipine ER, verapamil ER and digoxin show 'QL' notes in their entries.
    Devices & suppliesMany lancets, meters, pen needles and insulin syringes are marked QL in the device/supplies sections.
    Vitamins & prenatal productsMultiple OTC vitamins and prenatal formulations are listed with 'QL' in the vitamins section.
    Note

    Legend — coverage note meanings

    Legend shorthand (PA, QL, AL, DO, SP, OTC) conveys coverage controls. Use the legend to interpret whether prior authorization, quantity limits, age limits, dispensing or specialty routing apply.

    • PA = Prior Authorization required
    • QL = Quantity Limit
    • AL = Age Limit
    • DO = Dispense as directed / dispensing program indicator
    • SP = Specialty product routing
    • OTC = Over-the-counter status
    Step Therapy

    Quantity limit and step/dispensing indicators

    Quantity limits (QL) and step/alternative-therapy indicators (AL, DO) are present across the listing. QL flags may require clinical justification for override; AL flags restrict based on member age. DO may indicate dispensing program or site-of-care requirements.

    • QL may limit allowed quantity per fill or time period
    • AL enforces age-based limits (e.g., pediatric vs adult formulations)
    • DO indicates dispensing or site-of-care/dispensing program constraints
    Documentation Required

    Documentation expectations for PA/SP/QL items

    Documentation supporting PA/SP/QL requests is expected. Include clinical rationale, prior therapies tried (when applicable), dosing, and member-specific information to facilitate approval. Specialty products often require additional ordering/provider certifications and specialty pharmacy routing details.

    • Attach relevant medical records and prior therapy history
    • For SP items, include preferred specialty pharmacy and shipping/site-of-care details
    • Be prepared to submit age verification for AL items and dosing calculations for QL overrides
    Prior Authorization

    Injectable biologics and on-body injectors

    Injectable biologics, on-body injectors and device-related products are frequently flagged PA; SP; QL. Examples include on-body injectors and biologic prefills — these require prior authorization and may have specialty distribution or quantity controls.

    • On-body injectors: UDENYCA examples (PA; SP; QL)
    • Injectable biologics: ARANESP, HAEGARDA, TAKHZYRO (PA; SP; QL)
    Prior Authorization

    Prior authorization required for selected injectables and specialty antivirals

    Selected injectables, specialty antivirals, and other high-cost agents require prior authorization. Examples from the list include oncology biologics, selected antivirals and long‑acting injectables.

    • Oncology/specialty: MVASI (PA; SP), mitoxantrone (SP)
    • Antivirals/specialty antivirals: select antiviral group entries showing SP/PA indicators
    • Long‑acting injectables: RISPERDAL CONSTA, INVEGA SUSTENNA (PA; AL; QL)
    Prior Authorization

    Prior authorization required for select CGM and device items

    Continuous glucose monitoring (CGM) devices, sensors and associated transmitters are flagged PA and QL in the formulary. Prior authorization is required for CGM receivers, sensors and transmitters; coverage may be subject to quantity limits and clinical criteria.

    • Dexcom G6/G7 receivers, sensors, transmitters — Notes = PA; QL
    • FreeStyle Libre sensors/readers — Notes = PA; QL
    • Omnipod kits and pods — Notes = PA; QL
    Denial Risk

    Denial triggers linked to Notes flags

    Claims for items annotated with PA/QL/AL without an approved authorization or supporting documentation are at risk of denial. Ensure the appropriate PA number and documentation are submitted with the claim or prior to dispensing to avoid denial.

    • Denial triggers: missing PA number, exceeded QL, age mismatch for AL items
    • Operational note: verify PA before dispensing and document in chart
    Step Therapy

    Step therapy and alternative-therapy flags — provider action

    When a product listing includes step therapy or alternative-therapy flags (AL, DO, QL), no explicit step sequence may be shown in this section. Providers should consult the payer's clinical policy or prior authorization portal for step edits and required trialed therapies.

    • Step therapy sequences are not included here — check clinical policies
    • Examples: dermatologic immunomodulators (PA; AL; QL) show flags but no sequence in this listing
    Operational impactClaims for PA-marked products may be denied without an approved prior authorization per the legend notes.
    inv-61: Quantity Limit (QL) — coverage limited to specified quantity
    DefinitionQL = Quantity Limit; denotes the payer restricts the amount of product dispensed over a defined period (specific numeric limits not shown here).
    Where seenApplied broadly across drug classes and devices (e.g., topicals, cardiovascular agents, CGM sensors/transmitters, lancets).
    Documentation noteDocumentation supporting medical necessity may be required when requesting quantities above the plan's QL.
    inv-62: Specialty (SP) — special handling/distribution or specialty tier
    DefinitionSP = Specialty; indicates specialty pharmacy handling, special distribution, or specialty drug tier routing is required.
    ExamplesProducts marked SP include certain oncology agents, specialty biologics (e.g., DUPIXENT, NORDITROPIN) and HAE therapies (HAEGARDA, TAKHZYRO).
    ImplicationSP items often require specialty channel documentation and may be routed to specialty pharmacies per payer processes.
    inv-63: Age Limit (AL) — coverage restricted by age
    DefinitionAL = Age Limit or Additional Limitation; indicates coverage is restricted by age or has another specified administrative limitation.
    ExamplesChild-specific formulations (e.g., COMIRNATY 5–11 years) and some nasal/OTC pediatric products are annotated with AL.
    Operational effectWhen AL appears, coverage and any quantity or PA rules may vary by patient age as noted in the formulary entry.
    inv-64: Designated Other (DO) — document-specific designation note
    DefinitionDO = Designated Other (document-specific designation); used in the legend for dispense/financial or programmatic directives specific to listed items.
    UsageDO appears alongside other notes (e.g., DO; QL) for certain oral tablets or formulations to indicate dispensing or program restrictions.
    Provider actionFollow the DO designation as part of adjudication and refer to full policy for any plan-specific dispensing instructions.
    inv-65: PA / QL / AL / DO / SP — combined legend annotations
    Legend summaryPA = prior authorization; QL = quantity limit; AL = age limit/additional limitation; DO = dispense/designation note; SP = specialty — these shorthand notes annotate formulary entries.
    FunctionThe combined legend flags indicate required prior authorization, quantity restrictions, specialty routing, age restrictions, or other dispense directives.
    Provider implicationProviders and pharmacies must honor these annotations during prescribing, dispensing, and claims adjudication.
    inv-66: Formulary note abbreviations — QL, PA, DO, AL, OTC explained
    QLQuantity Limit — plan restricts the amount dispensed (note 'QL' appears next to many drug and device entries).
    PAPrior Authorization — payer approval required before coverage for PA-marked products.
    DO/AL/OTCDO = dispense/designation note; AL = age limit; OTC = over-the-counter (non-prescription availability) — all appear as short notes in the formulary legend.
    inv-67: PA — Prior Authorization definition (simple)
    PA (simple)PA = Prior Authorization — payer approval required before coverage; appears next to multiple formulary entries.
    ContextUsed on specialty biologics, certain injectables and other therapies where pre-approval is required.
    ConsequenceClaims may be denied if PA is not obtained prior to dispensing.
    inv-68: QL — Quantity Limit definition (simple)
    QL (simple)QL = Quantity Limit — denotes restrictions on the amount dispensed per time period; many entries show QL without numeric limits in this excerpt.
    Where appliedApplied across drug classes and device consumables in the legend (topicals, cardiovascular agents, consumables, vitamins).
    Provider noteRequests exceeding QL may require supporting documentation or prior authorization per plan rules.
    inv-69: OTC — Over-The-Counter definition (simple)
    OTC (simple)OTC = Over-The-Counter — non-prescription availability is indicated for many listed products (e.g., antihistamines, lubricants, some acid reducers).
    Common entriesOTC appears on many topical, nasal, ophthalmic, vitamin and acid-reducer products in the legend.
    Coverage noteOTC designation does not preclude QL or other notes; OTC items may still have quantity limits.
    inv-70: SP — Specialty definition (simple)
    SP (simple)SP = Specialty — indicates specialty pharmacy channel or special handling/distribution is required for the product.
    ExamplesAppears next to biologics, HAE products, and certain injectables (e.g., DUPIXENT, HAE therapies, NORDITROPIN).
    Operational effectSP items typically require specialty pharmacy documentation and routing for dispensing and billing.
    inv-71: AL — Additional Limitation / Age Limit definition (simple)
    AL (simple)AL = Age Limit or Additional Limitation — indicates coverage restrictions by patient age or other administrative limitations.
    ExamplesUsed for pediatric formulations and some vaccines (e.g., COMIRNATY 5–11 years marked AL) and certain antipsychotic injectables.
    EffectWhen AL is present, coverage and any PA/QL rules may vary by the age noted in the full policy or product entry.
    inv-72: PA (legend occurrences) — PA shorthand appears in multiple header chunks
    PA occurrences'PA' appears repeatedly in header and line-item notes across the legend (e.g., REPATHA, DUPIXENT, various injectables), signaling pre-approval requirement.
    SectionsPA is used in multiple therapeutic sections including biologics, antivirals, specialty injectables, and devices.
    Provider implicationProviders must obtain PA per plan processes to avoid claim denials for items with the PA note.
    inv-73: QL (legend occurrences) — QL shorthand appears in multiple chunks
    QL occurrences'QL' is pervasive across line-items (topicals, OTCs, vaccines, devices, specialty agents) indicating quantity limits are widely applied.
    ExamplesSeen on cetirizine, clobetasol, REPATHA, vaccine entries and many device consumables.
    InterpretationQL flags require adherence to the payer's quantity limits during adjudication; numeric limits are available in the full policy or system tables.
    inv-74: OTC (legend occurrences) — OTC shorthand appears in multiple chunks
    OTC occurrences'OTC' is frequently used in the legend for antihistamines, lubricants, vitamins, and many consumer-facing products.
    Overlap with QLMany OTC items also carry 'QL' indicating OTC availability does not exempt them from quantity limits.
    Provider noteOTC designation informs prescribing and coverage but check QL/PA notes for adjudication requirements.
    inv-75: SP (legend occurrences) — SP shorthand appears in multiple chunks
    SP occurrences'SP' flags appear with specialty biologics and HAE/hemostatic agents (e.g., NORDITROPIN, HAEGARDA, ARANESP), indicating specialty routing.
    Common pairingSP is often paired with PA and QL (e.g., PA; SP; QL) for injectable specialty therapies.
    Routing implicationWhen SP is present, the product is intended for specialty pharmacy channels and may have additional documentation requirements.
    inv-76: OTC (device/consumable context) — OTC definition in device listings
    OTC in device contextOTC in device/consumable listings (e.g., many lancets, control solutions) marks items as available without prescription while still subject to QL.
    ExamplesAssure Lance, ACCU-CHEK lancets, control solutions and many lancing devices are noted OTC; QL.
    Adjudication noteEven OTC device items may carry QL or PA notes affecting coverage and refill frequency.
    inv-77: QL (device/consumable context) — QL definition in device listings
    QL in device listings'QL' appears extensively in device/supplies sections (lancets, meters, pen needles, control solutions) indicating quantity controls for consumables.
    ExamplesACCU-CHEK Fastclix, FORA lancets, BD autoshield devices and many lancing devices include QL notes.
    Coverage implicationPharmacies should apply program quantity controls for these consumables during adjudication.
    inv-78: PA (device/consumable context) — PA definition in device listings
    PA in device listings'PA' annotates select devices (e.g., CGM sensors/receivers, Omnipod kits, certain insulin syringes) indicating prior authorization is required before coverage.
    ExamplesDexcom G6/G7 sensors and receivers, Omnipod pods/kits and some meter kits are marked PA; QL.
    RiskClaims for these device items may be denied without PA per the legend notes.
    inv-79: cross-reference note — reference to master product/group listings
    Cross-reference noteSome entries reference master product/group listings (e.g., Advocate Lancets, Advocate Insulin Syringe) as grouping keys for multiple SKUs.
    UsageThese references indicate that grouped brand/generic families are managed collectively for coverage notes and QL application.
    Provider implicationCheck the referenced master listing when adjudicating specific SKU claims under the group name.
    inv-80: OTC — over-the-counter definition (additional occurrence)
    OTC additional occurrenceOTC designation is reiterated across topical ophthalmic and device sections confirming frequent non-prescription status of many entries.
    ExamplesLubricant eye drops, many nasal sprays and anti-allergy OTC items are repeatedly marked OTC.
    Overlap with QLOTC items often still carry 'QL' indicating quantity limits may apply despite OTC status.
    inv-81: QL — quantity limit definition (additional occurrence)
    QL additional occurrenceThe QL shorthand is used across cardiovascular, topical and many other therapeutic groups to denote quantity restrictions.
    ExamplesIsradipine, verapamil ER, nifedipine ER and numerous topical agents are annotated QL.
    Operational noteSpecific numeric limits are maintained elsewhere in plan systems; the legend flags items subject to those limits.
    inv-82: PA — prior authorization definition (additional occurrence)
    PA additional occurrencePA appears across drug classes including antihyperlipidemics, migraine injectables and vitamins when plan pre-approval is required.
    ExamplesREPATHA, Aimovig, Emgality and some injectable immunotherapies are annotated PA.
    ConsequenceProviders must submit PA requests per payer processes to obtain coverage approval for PA-marked items.
    inv-83: Coverage note abbreviations — PA, QL, OTC, SP explained (chunks 198-204)
    Abbreviations (coverage notes)PA = prior authorization; QL = quantity limit; OTC = over-the-counter; SP = specialty — used to annotate coverage controls in the formulary legend.
    RoleThese abbreviations guide provider and pharmacy actions (PA requests, QL adherence, specialty routing).
    ReferenceLegend entries direct users to follow the payer's authorization and limit processes as indicated by these notes.
    inv-84: PA — legend occurrence (chunks 216-225, 232)
    PA legend occurrences'PA' is shown in multiple header and line-item notes for products across sections (e.g., vitamins, ophthalmic, neurology and specialty injectable sections).
    ExamplesAimovig, Emgality, AVONEX, BETASERON and other specialty injectables are annotated PA in their listings.
    DocumentationPA-marked products typically require submission of supporting clinical documentation per payer policy for approval.
    inv-85: QL — legend occurrence (chunks 216-219-233)
    QL legend occurrences'QL' flags appear in vitamins/prenatal, device and ophthalmic sections indicating quantity limits across multiple categories.
    ExamplesPrenatal vitamins, MVW products and many OTC eye products include QL annotations.
    Provider implicationPharmacies should apply plan quantity limits when adjudicating claims for QL-flagged items.
    inv-86: OTC — legend occurrence (chunks 216-222-230)
    OTC legend occurrences'OTC' is used extensively in the vitamins/prenatal and acid reducer sections and many consumer products to indicate non-prescription availability.
    ExamplesMany prenatal, acid reducer and topical lubricant products are designated OTC in the legend.
    NoteEven OTC-labeled items may carry QL or PA annotations affecting coverage.
    inv-87: SP — specialty definition occurrence (chunk 225)
    SP occurrence'SP' appears with specialty therapies in the legend (e.g., certain neuromuscular and specialty agent listings) indicating specialty channel management.
    ExampleRiluzole is listed with PA; SP; QL suggesting specialty handling among other controls.
    ImplicationSpecialty routing and documentation requirements should be followed for SP-marked items.
    inv-88: AL — age limit/additional limitation occurrence (chunks 226-228)
    AL occurrence'AL' (age limit/additional limitation) appears with pediatric and vaccine-related entries and some nasal/OTC products, indicating age-based coverage restrictions.
    ExamplesBABY AYR saline, FLONASE children's formulations and several vaccines carry AL or AL-related notes.
    ActionConfirm patient age and applicable AL restrictions when adjudicating or requesting prior authorization for AL-flagged items.
    inv-89: PA — legend occurrence (chunks 235-241)
    PA occurrences summary'PA' appears across ophthalmic, device and specialty sections (e.g., LASTACAFT, AVONEX) indicating a widespread PA requirement for diverse product types.
    Denial riskDispensing PA-marked items without approval may result in claim denial per the legend notes.
    Provider stepSubmit PA requests per payer instructions when the 'PA' note is present to secure coverage.
    inv-90: QL — legend occurrence (chunks 235-241)
    QL occurrences summary'QL' recurs alongside many device, ophthalmic and injectable entries (e.g., LASTACAFT, AVONEX) indicating quantity limits apply across categories.
    ExamplesOphthalmic solutions, injectables and device consumables frequently include QL in their entries.
    Operational noteSpecific numeric QLs are managed by the plan and should be referenced in adjudication systems or full policy documents.
    inv-91: SP — legend occurrence (chunk 241)
    SP occurrences'SP' appears with multiple injectable and specialty therapy entries (e.g., AVONEX, HAE therapies) denoting specialty pharmacy routing.
    Co-occurrenceSP commonly co-occurs with PA and QL (PA; SP; QL) for high-cost specialty agents.
    Provider guidanceRoute SP-marked products to specialty channels and provide required specialty documentation for coverage.
    inv-92: OTC — legend occurrence (chunks 235-251)
    OTC frequent occurrenceOTC is one of the most common annotations, applied to topical ophthalmic lubricants, nasal sprays, vitamins and many device consumables.
    Overlap with QL/PAMany OTC items also carry QL or PA flags (e.g., TRUEPLUS pen needles show PA; OTC; QL), so OTC status alone does not guarantee unrestricted coverage.
    ImplicationCheck all notes (OTC, QL, PA) on a line-item to determine coverage and adjudication requirements.
    inv-93: OTC — legend occurrence (chunk 252)
    OTC single occurrenceOTC is reiterated in the acid reducer and gastrointestinal sections indicating non-prescription availability for many formulations.
    ExamplesGoodsense esomeprazole, omeprazole and lansoprazole OTC variants are explicitly marked OTC in the legend.
    Coverage noteOTC entries may still be subject to QL as noted in adjacent annotations.
    inv-94: PA/QL/AL — combined legend definitions (chunk 256)
    Combined definitions (chunk 256)PA = prior authorization required; QL = quantity limit; AL = age limit — used together on entries to indicate multiple concurrent controls.
    ExamplesVaccine and epinephrine listings may use PA/QL/AL combinations to reflect age limits and authorization/quantity controls.
    Provider actionWhen multiple notes appear together (PA/QL/AL), follow each applicable process (obtain PA, respect QL, verify age) before dispensing.
    Coverage noteImplication
    Many entries annotated with OTC, QL, or PA (e.g., acid reducer OTC listings)
    This excerpt contains no explicit step-therapy sequences; annotations indicate OTC status, quantity limits, or prior authorization where noted
    Coverage noteExamplesImplication
    PA; SP; QL
    AVONEX, BETASERON, dimethyl fumarate, glatiramer, REBIF, TERIFLUNOMIDE noted PA; SP; QL
    Specialty agents flagged PA/SP/QL are subject to prior authorization, specialty pharmacy routing, and quantity limits; specific step or channel workflows are not detailed in this fragment
    Coverage noteObservation
    Listings are at the product level with Notes flags (PA, QL, SP, DO, AL)
    Entries are listing-level annotations; no explicit step therapy sequences appear in the provided segments
    Reference chunkSee REPATHA entries in the antihyperlipidemic section where PA; QL are specified.
    inv-107: Multiple listed products — QL annotation present
    Multiple products flagged QLAcross antipsychotic, antiviral and psychiatric listings multiple products show the 'QL' annotation indicating quantity limits apply.
    ExamplesLong-acting injectables (INVEGA SUSTENNA), HIV agents (MAVYRET) and antipsychotics are among many items with QL remarks.
    Operational noteQL flags are pervasive and should be checked for each line-item when adjudicating claims.
    inv-108: nifedipine ER, verapamil, digoxin (examples) — QL indicated
    Cardiovascular examplesNifedipine ER, verapamil ER and digoxin entries include QL annotations in the cardiovascular/cardiotonics sections.
    ImplicationQuantity limits apply to select antihypertensive and cardiotonic agents per the legend.
    Provider actionCheck plan-specific QL values in adjudication systems for these agents before dispensing.
    inv-109: multiple topicals and OTC items — QL flag present
    Topicals & OTC itemsMultiple topical dermatologic products and many OTC items (e.g., hydrocortisone, clotrimazole, docosanol) carry the QL flag in the legend.
    ExamplesClobetasol, clotrimazole, hydrocortisone and docosanol entries are annotated QL (and many OTCs show OTC; QL).
    NoteSpecific numeric limits are not provided in this excerpt; the QL flag denotes that limits exist within plan systems.
    inv-110: selected specialty injectables — QL flag present
    Specialty injectables QLSelected specialty injectables and HAE/hemostatic agents (e.g., HAEGARDA, UDENYCA, BERINERT) include QL annotations alongside PA and SP.
    ExamplesHAEGARDA, RUCONEST, UDENYCA and other specialty injectables show PA; SP; QL indicating concurrent controls.
    Coverage implicationSpecialty injectables may require PA, specialty routing and are subject to quantity limits as noted.
    inv-111: Multiple listed OTC and prescription items — QL indicated via 'QL' note
    OTC & prescription itemsMultiple OTC and prescription items (iron supplements, vitamin B12, phenobarbital, etc.) are annotated with QL in the legend.
    ExamplesFERATE, ferrous products, phenobarbital and DROXIA entries include QL or PA; QL annotations.
    InterpretationQL flags across both OTC and Rx categories signal the payer enforces limits regardless of prescription status.
    inv-112: multiple listed consumables (lancets, syringes, swabs) — QL indicated
    Consumables QLLancets, lancing devices, pen needles and insulin syringes are repeatedly marked QL (specific limits not shown here).
    ExamplesASSURE LANCE, AUTOLET devices, BD insulin syringes and numerous branded lancets are annotated OTC; QL or PA; QL.
    Operational impactPharmacies should apply quantity controls when dispensing consumables as indicated by the QL note.
    inv-113: Multiple listed items (lancets, meters, control solutions) — QL specified in legend
    Meters & control solutionsDiagnostic test strips, control solutions and meter kits are flagged with QL in the devices section (e.g., ACCU-CHEK, FORA, TRUEPLUS entries).
    ExamplesACCU-CHEK Guide kits, FORA control solutions and TRUEPLUS pen needles/syringes include QL/PA annotations.
    Provider guidanceQuantity limits affect frequency of supply for meters and test supplies; follow plan quantity controls during ordering and dispensing.
    inv-114: multiple OTC items — QL annotated
    OTC vitamins/prenatals QLMany prenatal and multivitamin products are flagged OTC and QL (e.g., CERTAVITE, MVW formulations, classic prenatal), signifying quantity limits apply to OTC vitamins.
    ExamplesClassic prenatal, CVS prenatal gummy and MVW Complete formulations are annotated OTC; QL.
    Adjudication notePharmacies should check QL when dispensing prenatal vitamins despite OTC status.
    inv-115: multiple OTC vitamins/prenatal products — QL indicated
    Vitamins/prenatal examplesMultiple prenatal and multivitamin products are listed with OTC; QL notations across the vitamins section.
    ImplicationQuantity limits apply to many vitamin/prenatal products even when OTC-designated.
    Operational guidanceRefer to plan systems for numeric QL values when dispensing these items.
    inv-116: select ophthalmic and specialty agents — QL designated where noted
    Ophthalmic & specialty agentsSelect ophthalmic agents and specialty injectables are annotated QL (e.g., LASTACAFT, certain lubricants and specialty injectables like AVONEX have QL notes).
    ExamplesLASTACAFT shows PA; OTC; QL and AVONEX is listed PA; SP; QL, indicating quantity limits across both ophthalmic and specialty categories.
    Provider actionWhen QL appears with PA/SP, follow all applicable processes (PA submission, specialty routing and QL adherence) before dispensing.
    inv-117: Various listed products — QL flag present; specific limits not provided
    Various products flagged QLA broad set of listed products across sections carry the QL flag; the excerpt does not include numeric limits but consistently marks items as QL.
    Sections affectedTopicals, devices, ophthalmic, vitamins, specialty injectables and GI/acid reducer categories all include QL-flagged items.
    Next stepLookup numeric QL values in the plan's adjudication tables or full formulary documentation to determine exact limits.
    inv-118: Multiple OTC items and select vaccines/epinephrine — QL flagged where applicable
    OTC & vaccines QLMultiple OTC acid-reducers and select vaccines/epinephrine entries are flagged QL where applicable (e.g., some vaccine entries show AL; QL).
    ExamplesGoodsense esomeprazole OTC items and PNEUMOVAX/COMIRNATY vaccine entries include AL and/or QL annotations.
    ActionFor vaccines and epinephrine auto-injectors with QL/AL/PA notes, verify age restrictions and any required prior authorization before administration or billing.

    When an item is marked SP in the legend, route the prescription through the specialty pharmacy channel and provide specialty documentation as required by the payer.